Dr. Peter Beitsch on Pertuzumab in the Luminal Subtype of HER2-Positive Breast Cancer

Dr. Peter Beitsch on Pertuzumab in Luminal Subtype Breast CancerПодробнее

Dr. Pat Whitworth on Importance of the Luminal Subtype in Breast CanceПодробнее

Pertuzumab, trastuzumab and cyclophosphamide in older patients with HER2+ breast cancerПодробнее

Dr. Pegram on Pertuzumab Plus Trastuzumab and Chemotherapy in Breast CancerПодробнее

Dr. Pegram on Pertuzumab Combination for HER2-Positive Breast CancerПодробнее

Dr. Kolberg on Cost-Effectiveness of Pertuzumab in HER2-Positive Breast CancerПодробнее

Dr. Peter Beitsch on the Benefits of Grouping Patients With Breast Cancer by Subtype for TrialsПодробнее

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancerПодробнее

How Perjeta (Pertuzumab) is Used to Treat HER2-Positive Breast CancerПодробнее

Study of Atezolizumab with Pertuzumab and Trastuzumab in HER2- Positive Metastatic Breast CancerПодробнее

Dr. Yee on Neoadjuvant Pertuzumab in HER2-Positive Breast CancerПодробнее

Dr. Aithal on Breast Cancer SubtypesПодробнее

DESTINY-Breast07: T-DXd+/- pertuzumab in patients with metastatic HER2+ breast cancerПодробнее

CLEOPATRA: pertuzumab, trastuzumab & chemo for HER2+ mBCПодробнее

Dr. Mark Pegram on Combining Trastuzumab and PertuzumabПодробнее

Experts Comment, Agendia Breast Cancer Assays - Peter Beitsch, MDПодробнее

Optimizing HER2-Positive Breast Cancer Therapy: Balancing Efficacy and ToxicityПодробнее

Dr. Hamilton Discusses Challenges With Approved Treatments for HER2-Positive Breast CancerПодробнее

PRECIOUS: pertuzumab retreatment in patients with HER+ breast cancerПодробнее